又一百亿赛道应用受挫,mRNA国内企业何去何从?

第一财经
17 Dec 2024

mRNA领先企业Moderna旗下两款呼吸道合胞病毒(RSV)疫苗的临床试验日前被叫停,令这一技术在该赛道的应用前景蒙上了一层阴影。12月10日,美国FDA在发布的简报中对Moderna 的RSV mRNA疫苗的安全性提出质疑,称在候选疫苗mRNA-1345和mRNA-1365中观察到重症下呼吸道感染病例的不平衡,并暂停所有针对婴幼儿的RSV疫苗临床试验,这一消息导致Moderna当天股价大幅下挫...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10